SG11201810333UA - Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders - Google Patents

Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders

Info

Publication number
SG11201810333UA
SG11201810333UA SG11201810333UA SG11201810333UA SG11201810333UA SG 11201810333U A SG11201810333U A SG 11201810333UA SG 11201810333U A SG11201810333U A SG 11201810333UA SG 11201810333U A SG11201810333U A SG 11201810333UA SG 11201810333U A SG11201810333U A SG 11201810333UA
Authority
SG
Singapore
Prior art keywords
international
new york
gansevoort
therapeutics
street
Prior art date
Application number
SG11201810333UA
Inventor
Michael Weiss
Hari Miskin
Peter Sportelli
Original Assignee
Tg Therapeutics Inc
Rhizen Pharmaceuticals Sa
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tg Therapeutics Inc, Rhizen Pharmaceuticals Sa, Lab Francais Du Fractionnement filed Critical Tg Therapeutics Inc
Publication of SG11201810333UA publication Critical patent/SG11201810333UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/205843 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 31/00 (2006.01) A61K 31/4155 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 39/395 (2006.01) A61K 31/416 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2017/034855 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 26 May 2017 (26.05.2017) — with amended claims (Art. 190)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/342,822 27 May 2016 (27.05.2016) US (71) Applicants: TG THERAPEUTICS, INC. [US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). RHIZEN PHARMACEUTICALS SA [CH/CH]; Fritz Courvoisier 40, 2300 La Chaux de Fonds (CH). LABO- RATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES [FR/FR]; 3 Avenue des Tropiques, 91940 Les Ulis (FR). Inventors: WEISS, Michael, S.; c/o TG Therapeutics, Inc., 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). = (72) MISKIN, Hari, P.; c/o TG Therapeutics, Inc., 2 Gansevoort = — Street, 9th Floor, New York, NY 10014 (US). SPORTEL- LI, Peter; c/o TG Therapeutics, Inc., 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). =_ Agent: STEFFE, Eric, K. et al.; Sterne, Kessler, Goldstein (74) & Fox P.L.L.C, 1100 New York Avenue, NW, Washington, DC 20005 (US). = Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = — SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — - UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, M 71' (54) Title: COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBI- in c:::: ) TOR TO TREAT B-CELL PROLIFERATIVE DISORDERS el ----. (57) : Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of IN Il agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's © tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well N as kits for carrying out the claimed methods, are also provided. 0
SG11201810333UA 2016-05-27 2017-05-26 Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders SG11201810333UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342822P 2016-05-27 2016-05-27
PCT/US2017/034855 WO2017205843A1 (en) 2016-05-27 2017-05-26 Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders

Publications (1)

Publication Number Publication Date
SG11201810333UA true SG11201810333UA (en) 2018-12-28

Family

ID=60412660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810333UA SG11201810333UA (en) 2016-05-27 2017-05-26 Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders

Country Status (14)

Country Link
US (2) US10966977B2 (en)
EP (1) EP3463318A4 (en)
JP (1) JP2019517485A (en)
KR (1) KR20190015351A (en)
CN (1) CN109640964A (en)
AU (1) AU2017268839A1 (en)
BR (1) BR112018074238A2 (en)
CA (1) CA3024123A1 (en)
CL (1) CL2018003349A1 (en)
EA (1) EA201892284A1 (en)
IL (1) IL263239A (en)
MX (1) MX2018014577A (en)
SG (1) SG11201810333UA (en)
WO (1) WO2017205843A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102436875B1 (en) * 2017-12-08 2022-08-26 주식회사 보령 Composition comprising a PI3 kinase inhibitor and a BCL-2 inhibitor
KR20210021348A (en) * 2018-06-15 2021-02-25 얀센 파마슈티카 엔.브이. Formulation/composition comprising ibrutinib
CN108743947B (en) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 Pharmaceutical composition for treating B cell lymphoma
BR112022000684A2 (en) * 2019-07-15 2022-03-03 Johnson Matthey Plc Umbralisib monotosylate, process for preparing an amorphous form, amorphous form of umbralisib monotosylate, pharmaceutical composition, and, method of treating disease
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
JP2024513522A (en) * 2021-04-08 2024-03-25 アルティヴァ バイオセラピューティクス インコーポレイテッド Cancer treatment using NK cells and HER2 targeting antibodies
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
FR2844455B1 (en) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
SI2289936T1 (en) 2002-12-16 2017-10-30 Genentech, Inc. Immunoglobulin variants and uses thereof
FR2858235B1 (en) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS
US7663057B2 (en) 2004-02-19 2010-02-16 Nanosolar, Inc. Solution-based fabrication of photovoltaic cell
FR2879204B1 (en) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
US8543180B2 (en) 2006-05-03 2013-09-24 Covidien Lp Method and apparatus for total hemoglobin measurement
CN102887900B (en) 2006-09-22 2015-04-29 药品循环公司 Inhibitors of bruton's tyrosine kinase
MY173795A (en) 2009-11-05 2020-02-24 Incozen Therapeutics Pvt Ltd Novel benzopyran kinase modulators
MY169987A (en) 2012-07-04 2019-06-19 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
AU2013337733B2 (en) * 2012-11-02 2018-03-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
RS62136B1 (en) 2014-05-27 2021-08-31 Rhizen Pharmaceuticals S A Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
MX2017001656A (en) 2014-08-08 2017-07-24 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof.
TW201618773A (en) * 2014-08-11 2016-06-01 艾森塔製藥公司 Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a CDK4/6 inhibitor

Also Published As

Publication number Publication date
EP3463318A1 (en) 2019-04-10
IL263239A (en) 2018-12-31
WO2017205843A1 (en) 2017-11-30
US20210169878A1 (en) 2021-06-10
AU2017268839A1 (en) 2018-11-29
KR20190015351A (en) 2019-02-13
EP3463318A4 (en) 2020-01-01
EA201892284A1 (en) 2019-08-30
US20190175592A1 (en) 2019-06-13
JP2019517485A (en) 2019-06-24
CL2018003349A1 (en) 2019-03-15
MX2018014577A (en) 2019-05-20
BR112018074238A2 (en) 2019-04-16
US10966977B2 (en) 2021-04-06
CA3024123A1 (en) 2017-11-30
CN109640964A (en) 2019-04-16

Similar Documents

Publication Publication Date Title
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
SG11201909949XA (en) Targeted immunotolerance
SG11201811432WA (en) Rna for cancer therapy
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908391XA (en) Methods for modulating an immune response
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201811074RA (en) Nant cancer vaccine
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201907023UA (en) Method of reducing neutropenia
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201805001UA (en) Method of treating influenza a
SG11201809594WA (en) Nicotine particles and compositions
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors